



Commercial/Health Care Exchange Quantity Limit Criteria
Effective: May 8th, 2019

Quantity Limit Name: Oxervate

Products Affected: Oxervate (cenegermin-bkbj) 0.002% ophthalmic solution

Type of Quantity Limit:

- FDA maximum
- Usual Daily Frequency
- Split fill
- Other (Please specify): _____

Limits to be applied:

8 kits per affected eye per lifetime.

16 kits total per lifetime.

*Note: Reauthorization will not be approved as there have been no studies to document the efficacy of treatment beyond a single 8-week course.

References:

1. Oxervate [prescribing information]. Boston, MA: Dompé U.S. Inc.; April 2019.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	4/12/2019

Last Res. April 12th, 2019